Amalgamated Bank’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $859K | Sell |
33,969
-2,051
| -6% | -$45.1K | 0.01% | 1168 |
|
|
2026
Q1 | $802K | Sell |
36,020
-242
| -0.7% | -$5.78K | 0.01% | 1159 |
|
|
2025
Q4 | $969K | Sell |
36,262
-48
| -0.1% | -$1.15K | 0.01% | 1078 |
|
|
2025
Q3 | $775K | Buy |
36,310
+1,219
| +3% | +$28.8K | 0.01% | 1152 |
|
|
2025
Q2 | $757K | Buy |
35,091
+89
| +0.3% | +$1.65K | 0.01% | 1147 |
|
|
2025
Q1 | $581K | Buy |
35,002
+30,921
| +758% | +$562K | 0.01% | 1201 |
|
|
2024
Q4 | $75K | Sell |
4,081
-224
| -5% | -$3.62K | ﹤0.01% | 1755 |
|
|
2024
Q3 | $66K | Hold |
4,305
| – | – | ﹤0.01% | 1775 |
|
|
2024
Q2 | $70K | Buy |
4,305
+190
| +5% | +$3.07K | ﹤0.01% | 1785 |
|
|
2024
Q1 | $76K | Sell |
4,115
-13,346
| -76% | -$331K | ﹤0.01% | 1776 |
|
|
2023
Q4 | $547K | Sell |
17,461
-1,224
| -7% | -$29.2K | ﹤0.01% | 1407 |
|
|
2023
Q3 | $389K | Buy |
18,685
+276
| +1% | +$7.5K | ﹤0.01% | 1532 |
|
|
2023
Q2 | $441K | Buy |
18,409
+1,367
| +8% | +$30.4K | ﹤0.01% | 1496 |
|
|
2023
Q1 | $321K | Sell |
17,042
-2,838
| -14% | -$54K | ﹤0.01% | 1612 |
|
|
2022
Q4 | $316K | Buy |
19,880
+622
| +3% | +$9.72K | ﹤0.01% | 1673 |
|
|
2022
Q3 | $315K | Buy |
19,258
+307
| +2% | +$4.97K | ﹤0.01% | 1646 |
|
|
2022
Q2 | $267K | Sell |
18,951
-642
| -3% | -$12K | ﹤0.01% | 1744 |
|
|
2022
Q1 | $475K | Sell |
19,593
-1,471
| -7% | -$35.6K | ﹤0.01% | 1564 |
|
|
2021
Q4 | $492K | Sell |
21,064
-311
| -1% | -$6.25K | ﹤0.01% | 1583 |
|
|
2021
Q3 | $355K | Sell |
21,375
-1,228
| -5% | -$23.7K | ﹤0.01% | 1767 |
|
|
2021
Q2 | $551K | Buy |
22,603
+2,018
| +10% | +$45.5K | ﹤0.01% | 1595 |
|
|
2021
Q1 | $531K | Sell |
20,585
-1,795
| -8% | -$79K | 0.02% | 942 |
|
|
2020
Q4 | $1.2M | Sell |
22,380
-1
| -0% | -$50 | 0.05% | 434 |
|
|
2020
Q3 | $923K | Sell |
22,381
-295
| -1% | -$12.7K | 0.04% | 486 |
|
|
2020
Q2 | $1.1M | Buy |
22,676
+2,562
| +13% | +$123K | 0.05% | 384 |
|
|
2020
Q1 | $850K | Sell |
20,114
-661
| -3% | -$27.2K | 0.02% | 681 |
|
|
2019
Q4 | $889K | Buy |
20,775
+2,067
| +11% | +$89.9K | 0.02% | 848 |
|
|
2019
Q3 | $673K | Sell |
18,708
-219
| -1% | -$6.64K | 0.01% | 909 |
|
|
2019
Q2 | $506K | Buy |
18,927
+1,665
| +10% | +$42.5K | 0.01% | 1066 |
|
|
2019
Q1 | $463K | Buy |
17,262
+2,918
| +20% | +$68.1K | 0.01% | 1037 |
|
|
2018
Q4 | $232K | Buy |
+14,344
| New | +$279K | 0.01% | 1324 |
|
|
2018
Q3 | – | Sell |
-15,055
| Closed | -$230K | – | 1443 |
|
|
2018
Q2 | $230K | Sell |
15,055
-5,966
| -28% | -$106K | 0.01% | 1479 |
|
|
2018
Q1 | $472K | Buy |
21,021
+1,338
| +7% | +$37K | 0.01% | 986 |
|
|
2017
Q4 | $593K | Buy |
19,683
+1,410
| +8% | +$45.1K | 0.02% | 913 |
|
|
2017
Q3 | $688K | Buy |
18,273
+392
| +2% | +$12.8K | 0.02% | 821 |
|
|
2017
Q2 | $499K | Buy |
17,881
+3,912
| +28% | +$117K | 0.02% | 946 |
|
|
2017
Q1 | $480K | Sell |
13,969
-3,076
| -18% | -$109K | 0.02% | 863 |
|
|
2016
Q4 | $492K | Buy |
17,045
+2,153
| +14% | +$57K | 0.02% | 842 |
|
|
2016
Q3 | $474K | Buy |
14,892
+458
| +3% | +$15.5K | 0.03% | 770 |
|
|
2016
Q2 | $460K | Buy |
14,434
+5,565
| +63% | +$186K | 0.03% | 771 |
|
|
2016
Q1 | $248K | Buy |
8,869
+1,200
| +16% | +$26.2K | 0.02% | 997 |
|
|
2015
Q4 | $273K | Sell |
7,669
-686
| -8% | -$24.2K | 0.03% | 851 |
|
|
2015
Q3 | $276K | Buy |
8,355
+112
| +1% | +$4.66K | 0.03% | 928 |
|
|
2015
Q2 | $345K | Buy |
8,243
+766
| +10% | +$29.6K | 0.03% | 852 |
|
|
2015
Q1 | $244K | Buy |
7,477
+307
| +4% | +$10.6K | 0.03% | 779 |
|
|
2014
Q4 | $228K | Buy |
+7,170
| New | +$203K | 0.04% | 736 |
|
Other funds holding ACAD
PAM
RHJA
GT
Amalgamated Bank's ACAD Position: Q2 2026 in Review
Amalgamated Bank reduced its Acadia Pharmaceuticals (ACAD) stake by 5.7% in Q2 2026, selling an estimated $45.1K and leaving 33,969 shares worth $859K. The position accounts for 0.01% of the portfolio, ranked #1168.
Amalgamated Bank first reported a position in ACAD in Q4 2014 and has held it in 46 quarters since. The position peaked at $1.2M in Q4 2020. 149 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.
- Amalgamated Bank held 33,969 shares of Acadia Pharmaceuticals worth $859K as of Q2 2026.
- Amalgamated Bank sold 2,051 Acadia Pharmaceuticals shares in Q2 2026, an estimated $45.1K.
- Acadia Pharmaceuticals made up 0.01% of Amalgamated Bank's portfolio in Q2 2026, its #1168 holding.
- Amalgamated Bank first reported a position in Acadia Pharmaceuticals in Q4 2014 and has held it in 46 quarters since.
- Amalgamated Bank's Acadia Pharmaceuticals position peaked at $1.2M in Q4 2020.
- 149 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.
Based on Amalgamated Bank's 13F filing for Q2 2026, filed 23 Jul 2026.